Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1994-12-06
1998-05-05
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
4241841, 4241931, 514 8, 514 23, 530395, A61K 3814, A61K 3900, A61K 3939, C07K 1482
Patent
active
057470480
ABSTRACT:
A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
REFERENCES:
patent: 4444744 (1984-04-01), Goldenberg
Kurosaka et al., JBC 263, 8724 (1988).
Kurosawa A., et al., FEBS Lett 215:137-139, 1987.
Hakomori et al., J. Biol. Chem. 258:11819-11822.
Ross et al., Journal of the National Cancer Institute, vol. 73, p. 731 (1984).
Nuti M, et al., Intl. J. Cancer 29:539-545, 1982.
Johnson VG, et al., Cancer Res. 46:850-857, 1986.
Thor A, et al., Cancer Res. 46:3118-3124, 1986.
Feizi, T., et al; Biochem. Soc. Trans. 12(4):591-6 (1984), "Mucin-type glycoproteins".
Hakomori, S., et al. Cancer Res. 45(6):2405-14 (1985) "Aberrant Glycosylation in Cancer Cell Membranes as Focused on Glycolipids: Overview and Perspectives".
Houghton, A.N. et al. PNAS USA 82:1242-46 (1985) "Mouse Monoclonal IgG3 Antibody Detecting GD3 Ganglioside: A Phase I Trial in Patients with Malignant Melanoma".
Schreiber, H. In Fundamental Immunology, W. F. Paul editor (1989). "Tumor Immunology" pp. 923-955.
Sundsmo, J.S. et al. Biochem. Biophys. Res. Comm, 68(3):799-806 (1976), "Lacto-N-Neotetrasylceramide (Paragloboside) as a Possible Tumor-Associated Surface Antigen . . . ".
Gupta, R. K. et al. Vaccine 11(3):293-306 (1993) "Adjuvants--a Balance Between Toxicity and Adjuvanicity".
Rabinovich, N. B. et al. Science 265:1401-4 (2 Sep. 1994), "Vaccine Technologies: View to the Future".
Dermer, G. B. Bio/Technology 12:320(Mar. 1994), "Another Anniverrsay of the War on Cancer".
Osband, M. E. et al., Immunol. Today 11(6):193-195 (1990), "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy".
Springer, Georg F., Science 224:1198-1206, "T and Tn, General Carcinoma Autoantigens", Jun. 1984.
Clausen Henrik
Hakomori Sen-itiroh
Kjeldsen Thomas J.
Singhal Anil
Takahashi Helio
Cunningham Thomas M.
The Biomembrane Institute
LandOfFree
Monoclonal antibodies and vaccine development directed to human does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies and vaccine development directed to human , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies and vaccine development directed to human will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51191